118
Participants
Start Date
September 30, 2009
Primary Completion Date
June 30, 2015
Study Completion Date
June 30, 2015
pasireotide LAR
Investigational drug pasireotide LAR was supplied in vials with 20 mg or 40 mg powder and 2 mL vehicle was supplied in ampoules for reconstitution.
Novartis Investigative Site, Westmead
Novartis Investigative Site, Fitzroy
Mount Sinai School of Medicine Study Coordinator, New York
Novartis Investigative Site, Berlin
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Berlin
Novartis Investigative Site, Marseille
Novartis Investigative Site, Mexico City
Novartis Investigative Site, Málaga
Novartis Investigative Site, Pessac
Novartis Investigative Site, Padua
Novartis Investigative Site, Cona
Novartis Investigative Site, Angers
Novartis Investigative Site, Reims
Novartis Investigative Site, Pisa
Novartis Investigative Site, Lille
Novartis Investigative Site, Ancona
Novartis Investigative Site, Frankfurt
Novartis Investigative Site, Strasbourg
Novartis Investigative Site, Bron
Novartis Investigative Site, München
Novartis Investigative Site, Ulm
Cedars Sinai Medical Center Cedars Sinai 4, Los Angeles
Cedars Sinai Medical Center The Pituitary Center (3), Los Angeles
Novartis Investigative Site, Erlangen
Novartis Investigative Site, Le Kremlin-Bicêtre
Stanford University Medical Center SC, Stanford
Novartis Investigative Site, Würzburg
Novartis Investigative Site, Moscow
Novartis Investigative Site, Moscow
Novartis Investigative Site, Saint Petersburg
Dana Farber Cancer Institute Deptof DanaFarberCancerInst(5), Boston
Swedish Medical Center Dept.ofSwedishMedicalCtr.(2), Seattle
Novartis Investigative Site, Buenos Aires
Novartis Investigative Site, Fortaleza
Novartis Investigative Site, Belo Horizonte
Novartis Investigative Site, Botucatu
Novartis Investigative Site, Halifax
Novartis Investigative Site, Montreal
Novartis Investigative Site, Roma
Novartis Investigative Site, Barcelona
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY